Biocept (BIOCQ) 10-Q 12 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 07, 2021
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		13,402,562
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36284
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0943522
Entity Address, Address Line One	9955 Mesa Rim Road
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	320-8200
Title of 12(b) Security	Common Stock, par value $.0001 per share
Entity Shell Company	false
Entity Current Reporting Status	Yes
Security Exchange Name	NASDAQ

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 14,197,547	$ 14,367,942
Accounts receivable, net	17,143,572	14,144,911
Inventories, net	3,258,594	1,929,624
Prepaid expenses and other current assets	697,724	2,151,527
Total current assets	35,297,437	32,594,004
Fixed assets, net	2,095,704	2,317,616
Lease right-of-use assets - operating	9,407,468	9,776,349
Lease right-of-use assets - finance	3,059,458	2,337,709
Other non-current assets	438,776	425,908
Total assets	50,298,843	47,451,586
Current liabilities:
Accounts payable	7,295,875	8,364,858
Accrued liabilities	3,437,575	3,165,669
Current portion of lease liabilities - finance	1,179,557	963,726
Total current liabilities	11,913,007	12,494,253
Non-current portion of lease liabilities - operating	9,798,146	9,805,361
Non-current portion of lease liabilities - finance	1,816,463	1,459,550
Total liabilities	23,527,616	23,759,164
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; 2,111 shares issued and outstanding at December 31, 2020 and March 31, 2021.
Common stock, $0.0001 par value, 150,000,000 authorized; 13,397,041 issued and outstanding at December 31, 2020; 13,402,562 issued and outstanding at March 31, 2021.	1,340	1,340
Additional paid-in capital	287,697,462	287,217,949
Accumulated deficit	(260,927,575)	(263,526,867)
Total shareholders’ equity	26,771,227	23,692,422
Total liabilities and shareholders’ equity	$ 50,298,843	$ 47,451,586

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,111	2,111
Preferred stock, shares outstanding	2,111	2,111
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	13,402,562	13,397,041
Common stock, shares outstanding	13,402,562	13,397,041

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Income/Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Net revenues	$ 17,756,190	$ 1,446,549
Costs and expenses:
Cost of revenues	9,005,856	2,946,858
Research and development expenses	1,042,725	1,312,676
General and administrative expenses	3,119,804	1,904,433
Sales and marketing expenses	1,923,272	1,465,115
Total costs and expenses	15,091,657	7,629,082
(Loss)/income from operations	2,664,533	(6,182,533)
Other expense:
Interest expense, net	(65,241)	(56,696)
Warrant inducement expense		(2,102,109)
Total other expense	(65,241)	(2,158,805)
(Loss)/income before income taxes	2,599,292	(8,341,338)
Net (loss)/income and comprehensive (loss)/income	2,599,292	(8,341,338)
Deemed dividend related to warrants down round provision		(2,774)
Net (loss)/income attributable to common shareholders	$ 2,599,292	$ (8,344,112)
Weighted-average shares outstanding used in computing net (loss)/income per share attributable to common shareholders:
Basic	13,400,007	7,899,991
Diluted	13,667,716	7,899,991
Net (loss)/income per common share:
Basic	$ 0.19	$ (1.06)
Diluted	$ 0.19	$ (1.06)

Condensed Statement of Sharehol

Condensed Statement of Shareholders' Equity (Unaudited) - USD ($)	Total	March 2, 2020 Financing Transaction [Member]	March 4, 2020 Financing Transaction [Member]	December 2019 Financing Transaction Overallotment [Member]	Common Stock [Member]	Common Stock [Member]Cashless Warrants [Member]	Common Stock [Member]March 2, 2020 Financing Transaction [Member]	Common Stock [Member]March 4, 2020 Financing Transaction [Member]	Common Stock [Member]December 2019 Financing Transaction Overallotment [Member]	SeriesA Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Cashless Warrants [Member]	Additional Paid-in Capital [Member]March 2, 2020 Financing Transaction [Member]	Additional Paid-in Capital [Member]March 4, 2020 Financing Transaction [Member]	Additional Paid-in Capital [Member]December 2019 Financing Transaction Overallotment [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2019	$ 11,200,643				$ 547						$ 256,917,285					$ (245,717,189)
Beginning balance, shares at Dec. 31, 2019					5,473,848					2,133
Stock-based compensation expense	142,964										142,964
Shares issued upon exercise of common stock warrants	2,306,708				$ 70	$ 61					2,306,638	$ (61)
Shares issued upon exercise of common stock warrants, shares					696,141	608,000
Deemed dividends related to warrants downround provision	2,774										2,774					(2,774)
Shares and warrants issued, net of issuance costs		$ 8,565,500	$ 6,093,561	$ 659,958			$ 230	$ 160	$ 19				$ 8,565,270	$ 6,093,401	$ 659,939
Shares and warrants issued, net of issuance costs, shares							2,300,000	1,600,000	192,750
Warrant inducement expense	2,102,109										2,102,109
Net income (loss)	(8,341,338)															(8,341,338)
Ending balance at Mar. 31, 2020	22,730,105				$ 1,087						276,790,319					(254,061,301)
Ending balance, shares at Mar. 31, 2020					10,870,739					2,133
Beginning balance at Dec. 31, 2019	11,200,643				$ 547						256,917,285					(245,717,189)
Beginning balance, shares at Dec. 31, 2019					5,473,848					2,133
Net income (loss)	(17,800,000)
Ending balance at Dec. 31, 2020	23,692,422				$ 1,340						287,217,949					(263,526,867)
Ending balance, shares at Dec. 31, 2020					13,397,041					2,111
Stock-based compensation expense	460,201										460,201
Shares issued upon exercise of common stock warrants	18,552										18,552
Shares issued upon exercise of common stock warrants, shares					5,304
Shares issued upon conversion of preferred stock, shares					23
Shares issued upon exercise of options	760										760
Shares issued upon exercise of options, shares					194
Net income (loss)	2,599,292															2,599,292
Ending balance at Mar. 31, 2021	$ 26,771,227				$ 1,340						$ 287,697,462					$ (260,927,575)
Ending balance, shares at Mar. 31, 2021					13,402,562					2,111

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Cash Flows from Operating Activities
Net (loss)/income	$ 2,599,292	$ (8,341,338)
Adjustments to reconcile net (loss)/income to net cash (used in)/provided by operating activities:
Depreciation and amortization	366,238	242,758
Amortization of right-of-use assets	361,666	(48,481)
Change in inventory reserve	(8,519)	25,240
Stock-based compensation	460,201	142,964
Warrant inducement expense		2,102,109
Loss (gain) on disposal of fixed assets	3,941
Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net	(2,998,661)	108,181
Inventory	(1,320,451)	(175,952)
Prepaid expenses and other current assets	1,453,803	(133,004)
Accounts payable	(332,723)	412,879
Accrued liabilities	271,906	385,784
Other non-current assets	(12,868)
Net cash (used in)/provided by operating activities	843,825	(5,278,860)	$ (19,800,000)
Cash Flows from Investing Activities:
Purchases of fixed assets	(712,202)	(18,507)
Net cash used in investing activities	(712,202)	(18,507)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants		14,659,061
Proceeds from exercise of common stock warrants	18,552	2,306,708
Proceeds from exercise of stock options	760
Payments on finance leases	(321,330)	(136,574)
Proceeds from exercise of overallotment warrants		659,958
Net cash provided by/(used in) financing activities	(302,018)	17,489,153
Net increase/(decrease) in cash	(170,395)	12,191,786
Cash at Beginning of Period	14,367,942	9,301,406	9,301,406
Cash at End of Period	14,197,547	21,493,192	$ 14,367,942
Cash paid during the period for:
Interest	$ 65,241	$ 56,696

Condensed Statements of Cash _2

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fixed assets purchased under finance leases	$ 894,000	$ 208,000
Purchases of fixed asset	$ 319,000	17,000
Proceeds from exercise of overallotment warrants		$ 659,958

The Company, Business Activitie

The Company, Business Activities and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
The Company, Business Activities and Basis of Presentation	1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and is an early-stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM , provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly owned subsidiary of the Company since July 23, 2013. The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. While the Company experienced increased revenue levels in 2020 and the first quarter in 2021 related to its COVID-19 testing business and attained net income for the first time in its operating history in the fourth quarter in 2020, and again in the first quarter of 2021, these results are not expected to be indicative of future results as the COVID-19 pandemic subsides. Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 31, 2021 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten. As such, all references to share and per share amounts in these financial statements and accompanying notes have been retroactively restated to reflect the one-for-ten reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-ten reverse stock split. A novel strain of coronavirus, or COVID COVID COVID Significant Accounting Policies During the three months ended March 31, 2021, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians and other healthcare providers, the Company provides services that benefit the patient. Patients do not typically enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, such as pharma or biotech organizations, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks, and for our RT-PCR COVID-19 testing, typically 48 hours or less. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three months ended March 31, 2020 and 2021. Further, although the Company believes that its estimate for contractual allowances and other reserves is appropriate, it is possible that the Company will experience an impact on cash collections as a result of the impact of the COVID-19 pandemic. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three months ended March 31, 2020 and 2021 disaggregated by source and nature are as follows: For the three months ended March 31, 2020 2021 Net revenues from contracted payers* $ 500,188 $ 6,313,884 Net revenues from non-contracted payers 817,413 11,341,163 Development services revenues 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190 *Includes Medicare, Medicare Advantage, and CARES Act as reimbursement amounts are fixed. Revenues for the three months ended March 31, 2021 included $17.7 million in commercial test revenue, which includes $16.8 million attributable to RT-PCR COVID-19 testing. For the three months ended March 31, 2020 2021 Net commercial revenues recognized upon delivery $ 1,317,601 $ 17,655,047 Development services revenues recognized upon delivery 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190 At December 31, 2020 and March 31, 2021, unbilled account receivables total approximately $4.5 million and $4.3 million, respectively. Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2020 and 2021 were as follows: For the three months ended March 31, 2020 2021 Medicare and Medicare Advantage/CARES Act 37 % 35 % Blue Cross Blue Shield 29 % 30 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2020 and March 31, 2021 were as follows: December 31, 2020 March 31, 2021 Medicare and Medicare Advantage/CARES Act 35 % 37 % Blue Cross Blue Shield 24 % 28 % Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Credit Losses (Topic 326).” ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables and investments, be represented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In May 2019, the FASB issued ASU No. 2019-05, “Financial Instruments—Credit Losses (Topic 326) Targeted Transition Relief,” which allows for a transition election on certain instruments. The guidance is effective for Small Reporting Companies for fiscal years beginning after December 15, 2022 and interim periods in those fiscal years. In November 2019, the FASB issued ASU No. 2019-11 which amends certain aspects of ASU No. 2016-13, including transition relief for trouble debt restructuring, among other topics. The Company is currently evaluating the impact of this pronouncement on its financial statements.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Liquidity	2. Liquidity As of March 31, 2021, cash totaled $14.2 million and the Company had an accumulated deficit of $260.9 million. For the year ended December 31, 2020 and the three months ended March 31, 2021, the Company had a net loss and net income of $17.8 million and $2.6 million, respectively, and had negative cash flows and cash generated from operations of $19.8 million and $844,000, respectively. At March 31, 2021, the Company had aggregate net interest-bearing indebtedness of $3.0 million, of which $1.2 million was due within one year, in addition to $3.4 million of other non-interest-bearing current liabilities. The Company has historically funded its operations through capital raises. However, the COVID-19 testing revenue during 2020 and through the first quarter of 2021, has provided the Company with increased levels of cash inflows from operations, and it is expected to continue, albeit at lower and declining levels, throughout at least the next twelve months. As a result, the Company believes that based on its current and planned cash usage, along with current COVID-19 testing revenues, its cash balances will support operations through the second quarter of 2022. As such, the Company determined that it is not probable based on projected cash flows that substantial doubt about the Company’s ability to continue as a going concern exists for the one-year period following the date that the financial statements for the three months ended March 31, 2021 were issued. The Company’s determination was based on estimates regarding expected COVID-19 testing volumes, which are uncertain and subject to change as more individuals are expected to be vaccinated and as the pandemic subsides. The Company used all information currently available to make this determination. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations. Based on current cash balances and current and planned cash usage, the Company determined that it is not probable that substantial doubt exists about the Company’s ability to continue as a going concern In order to meet its long-term operating requirements beyond the next twelve months, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. The Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all.

Sales of Equity Securities

Sales of Equity Securities	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Sales of Equity Securities	3. Sales of Equity Securities In January 2020, the Company issued an aggregate of 692,725 shares of its common stock pursuant to the exercise of certain warrants issued by the Company in February 2019 and March 2019, as part of a warrant repricing and exchange transaction. As part of the warrant repricing and exchange transaction, the Company issued an aggregate of 692,725 new warrants in exchange for the exercise of the February 2019 and March 2019 warrants and received net proceeds of approximately $2.3 million. As a result of the warrant repricing, the exercise price of warrants to purchase an aggregate of 89,657 shares of common stock issued by the Company in January 2018 was adjusted from $4.05 to $3.495 per share. In January 2020, the Company issued 192,750 shares of common stock pursuant to the partial exercise of the underwriters’ overallotment option from the Company’s December 2019 public offering. The net proceeds to the Company from the overallotment closing, was approximately $700,000. The warrants issued in connection with the warrant repricing and exchange transaction were considered inducement warrants and are classified in equity. In addition, the modification expense associated with the change in fair value due to the repricing of February and March 2019 warrants is recorded as inducement expense, which was approximately $191,000. The fair value of the warrants issued was approximately $1.9 million. The fair value of the inducement warrants and warrant modification of $2.1 million was expensed as warrant inducement expense in the accompanying statement of operations for the three months ended March 31, 2020. On March 2, 2020, the Company sold and issued 2,300,000 shares of its common stock at a negotiated purchase price of $4.00 per share in a registered direct offering and received net cash proceeds of approximately $8.6 million after deducting placement agent fees and other expenses. On March 4, 2020, the Company sold and issued 1,600,000 shares of its common stock at a negotiated purchase price of $4.10 per share in a registered direct offering and received net cash proceeds of approximately $6.1 million after deducting placement agent fees and other expenses.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $894,000 during the three months ended March 31, 2021 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates. Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on the present value of future lease payments based on contractual payment amounts and estimated market rates in effect. Other Fair Value Measurements As of the closing of the Company’s January 2020 warrant repricing and exchange transaction, the estimated grant date fair value of approximately $2.80 per share associated with the warrants to purchase up to 692,725 shares of common stock issued in the transaction, or a total of approximately $1.9 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $3.495 per share, are exercisable beginning 6 months from issuance and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 3.00 Exercise price $ 3.495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 % In addition to the inducement warrants issued in the Company’s January 2020 warrant repricing and exchange transaction, the Company adjusted the exercise prices of the February 2019 and March 2019 warrants from $12.00 and $12.50, respectively, to $3.495 to induce exercise of these warrants. This price modification triggered the requirement for modification accounting of these warrants. Based on the applicable guidance, the modification required the Company to value the modified February 2019 and March 2019 warrants immediately prior to the modification of the exercise price and immediately following the modification and record the difference between the resulting two values as warrant inducement expense. The estimated fair value prior to modification of the February 2019 and March 2019 warrants was approximately $2.70 per share, whereas the estimated fair value of the February 2019 warrants increased to $2.90 due to the adjustment of the exercise price, and the estimated fair value of the March 2019 warrants increased to $3.00 per share. There were 216,725 February 2019 warrants and 476,000 March 2019 warrants eligible for this price modification and the resulting modification expense recorded as warrant inducement expenses were $60,000 and $130,000, respectively.

Balance Sheet Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2021
Balance Sheet Components [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, March 31, 2020 2021 Inventories Raw materials $ 1,235,620 $ 2,406,901 Subassemblies 691,126 839,674 Finished goods 2,878 12,019 $ 1,929,624 $ 3,258,594 Fixed Assets Machinery and equipment $ 2,974,320 $ 2,962,742 Furniture and office equipment 156,987 156,987 Computer equipment and software 2,428,211 2,556,276 Leasehold improvements 570,173 95,990 Construction in process 761,221 485,359 Total fixed assets, gross 6,890,912 6,257,354 Less accumulated depreciation and amortization (4,573,296 ) (4,161,650 ) Total fixed assets, net $ 2,317,616 $ 2,095,704 Accrued Liabilities Accrued payroll $ 452,118 $ 772,342 Accrued vacation 868,557 952,885 Accrued bonuses 1,022,421 1,265,262 Accrued sales commissions 456,526 339,000 Accrued other 366,047 108,086 Total accrued liabilities $ 3,165,669 $ 3,437,575 During the three months ended March 31, 2021, machinery and equipment and leasehold improvements with a net book value of approximately $4,000 were disposed of and $712,000 of fixed assets were acquired.

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	6. Leases Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Fixed Assets on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Finance Leases The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight-line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $4,639,000 and $5,533,000 at December 31, 2020 and March 31, 2021, respectively. Total accumulated depreciation related to financed equipment was approximately $2,302,000 and $2,474,000 at December 31, 2020 and March 31, 2021, respectively, and total depreciation expense related to financed equipment during the three months ended March 31, 2020 and 2021 was approximately $146,000 and $172,000, respectively. In February 2020, the Company entered into finance leases for a total capitalized amount of $197,000 for three pieces of equipment . Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full in installments ranging from 48 to 60 monthly installments of $4,532 totaling approximately $265,000 through January 2025. In addition, in March 2020, the Company entered into a finance lease for a capitalized amount of $11,000 for an additional piece of equipment. Under the term of the equipment financing agreement, the principal amount plus interest are to be repaid in 48 monthly installments of $288 totaling approximately $14,000 through February 2024. During the three months ended March 31, 2021, the Company entered into finance leases for a total capitalized amount of $894,000 for four pieces of equipment. Under the terms of the financing agreements, which were accounted for as finance lease transactions, the principal balance plus interest for the equipment are to be paid in installments ranging from 36 to 60 monthly installments of $21,330 totaling approximately $1,064,000 through March 2026. Operating Lease The Company leases its primary laboratory and office facilities in San Diego, California. In accordance with the ASC 842 guidance, the facility lease is classified as an operating lease. From its inception until December 2020, the Company’s primary facilities were located at 5810 Nancy Ridge Road in San Diego, California (Nancy Ridge Facility). The average monthly cash payment for the operating lease was approximately $120,000 per month, and the lease term expired on July 31, 2020, but was extended as stated below. The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%. On June 5, 2020, the Company entered into a fifth amendment (the “Amendment”) to its lease agreement, dated March 31, 2004, relating to the Nancy Ridge Facility. Pursuant to the Amendment, the expiration date of the Lease was extended from July 31, 2020 to November 30, 2020. The monthly base rent during the extended term was the then current monthly rate paid by the Company. The Company agreed to pay additional rent and all other charges as set forth in the Lease through the expiration date. Pursuant to the extension of the expiration date of the lease, the Company recorded an additional lease right-of-use asset and lease liability of $482,000. In order to allow the Company adequate time to move its operations to its new facility, the Company entered into an additional extension related to the facility extending the lease until December 11, 2020 at the prorated amount of the current rent. On June 1, 2020, the Company entered into a lease for a 39,000 square foot headquarters, manufacturing and laboratory facility at 9955 Mesa Rim Road in San Diego, California. The lease commenced on December 1, 2020 and is for a term of 127 months from the commencement date. The lease includes a rent abatement period of seven months, from January 2021 through July of 2021, during which period the Company is exempted from paying the amount of base rent of $111,000. In addition, the lease stipulates an additional two months of lease abatement period in the event that the property is sold within the first six months of the initial lease period. In March 2021, the Company was notified that the original landlord has sold the building, hence the Company is eligible for an additional two months of rent abatement period. In addition, the landlord agreed to pay for certain preapproved leasehold improvement costs through a one-time leasehold improvement allowance of approximately $1,586,000, and an additional leasehold improvement allowance of approximately $1,586,000. The amount of additional leasehold improvement allowance of approximately $1,586,000 is to be paid back to the landlord during the term of the lease by the Company, amortized at an agreed upon annual rate of 7% as an additional rent payment of approximately $18,000 per month. The average monthly cash payment including payment for the additional leasehold improvement allowance for the lease is approximately $140,000 per month with initial monthly lease payments of $128,000 per month. The Company recorded a lease right-of-use asset and lease liability of $9,776,000 and $9,805,000, respectively, as of December 31, 2020, based on the present value of payments and an incremental borrowing rate of 12%. As the Company’s lease did not provide an implicit rate, the Company estimated the incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings. The Company recorded $1,631,000 and $361,000 in other current assets related to reimbursable leasehold improvement costs incurred as of December 31, 2020 and March 31, 2021, respectively. In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments. The following schedule sets forth the components of right-of-use lease assets as of December 31, 2020 and March 31, 2021 as follows: December 31, March 31, 2020 2021 Lease right-of-use assets: Operating $ 9,776,349 $ 9,407,468 Finance 2,337,709 3,059,458 Total $ 12,114,058 $ 12,466,926 The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2020 and March 31, 2021: December 31, March 31, 2020 2021 Current portion of lease liabilities: Operating $ — $ — Finance 963,726 1,179,557 Total $ 963,726 $ 1,179,557 The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2020 and March 31, 2021: December 31, March 31, 2020 2021 Long-term portion of lease liability: Operating $ 9,805,361 $ 9,798,146 Finance 1,459,550 1,816,463 Total $ 11,264,911 $ 11,614,609 The following schedule represents the components of lease expense for the three months ended March 31, 2020 and March 31, 2021: For the three months ended March 31, 2020 March 31, 2021 Lease cost Finance lease cost Amortization of right-of-use assets $ 144,530 $ 172,325 Interest on lease liabilities 56,701 65,241 Operating lease cost 318,005 414,802 Total $ 519,236 $ 652,368 The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of March 31, 2021: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2021 $ 981,740 $ 93,621 $ 495,590 2022 1,020,965 101,578 1,586,210 2023 873,830 85,427 1,629,025 2024 464,328 55,806 1,671,841 Thereafter 209,372 16,184 11,995,433 Total payments 3,550,235 352,616 17,378,099 Less amount representing interest (554,215 ) — (7,579,953 ) Present value of payments $ 2,996,020 $ 352,616 $ 9,798,146 The following schedule sets forth supplemental cash flow information related to operating and finance leases as of March 31, 2020 and March 31, 2021: For the three months ended March 31, 2020 March 31, 2021 Other information Operating cash flows from finance leases $ 56,701 $ 65,241 Operating cash flows from operating leases $ 366,487 $ 53,136 Financing cash flows from finance leases $ 136,574 $ 321,330 The aggregate weighted average remaining lease term was 3.27 years on finance leases and 10.17 years on operating leases as of March 31, 2021. The aggregate weighted average discount rate was 16.84% on finance leases and 12.0% on operating leases as of March 31, 2021. During the three months ended March 31, 2021, the Company added $894,000 of right of use assets in exchange for finance lease liabilities.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: the Amended and Restated 2013 Equity Incentive Plan, as amended, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. At the Company’s annual meeting of stockholders held on June 5, 2020, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 730,000 shares. In December 2020, the Company’s board of directors approved an increase of the number of inducement shares of common stock authorized for issuance under the 2013 Plan by 750,000 shares. 762,421 shares of the Company’s common stock were authorized exclusively for the issuance of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. As of March 31, 2021, under all plans, a total of 1,036,409 non-inducement shares were authorized for issuance, 988,101 shares had been issued with 993,172 non-inducement stock options and restricted stock units, or RSUs, underlying outstanding awards, and 32,220 non-inducement shares were available for grant. As of March 31, 2021, a total of 761,836 inducement shares were authorized for issuance, 268,882 inducement shares had been issued with 259,542 inducement stock options and RSUs underlying outstanding awards, and 502,210 inducement shares were available for grant under the 2013 Plan. Stock Options A summary of stock option activity for the three months ended March 31, 2021 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2020 1,078,704 $ 11.64 9.36 Granted 175,041 $ 5.70 Exercised — — Cancelled/forfeited/expired (40,461 ) $ 19.09 Outstanding at March 31, 2021 1,213,284 $ 10.44 9.31 Vested and unvested expected to vest at March 31, 2021 1,179,760 $ 10.60 9.31 The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2020 and March 31, 2021 were each $4,714 and $61,515, respectively. The assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2021 were as follows: Stock and exercise prices $5.09 - $6.03 Expected dividend yield 0.00% Discount rate-bond equivalent yield 0.52% – 1.15% Expected life (in years) 5.39 – 5.98 Expected volatility 164.0% - 170.1% Restricted Stock A summary of RSU activity for the three months ended March 31, 2021 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2020 36 $ 4,158 Granted — — Vested and issued — — Forfeited — — Outstanding at March 31, 2021 36 $ 4,158 Vested at March 31, 2021 36 $ 4,158 At March 31, 2021, the intrinsic values of RSUs outstanding and RSUs vested were each approximately $200. Of the 36 RSUs outstanding at March 31, 2021, Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended March 31, 2020 2021 Stock Options Cost of revenues $ 22,813 $ 94,264 Research and development expenses 24,435 44,316 General and administrative expenses 94,414 259,363 Sales and marketing expenses 1,302 62,258 Total expenses related to stock options 142,964 460,201 As of March 31, 2021, total unrecognized share-based compensation expense related to unvested stock options and RSUs was approximately $4,709,384 and is expected to be recognized over a weighted-average period of approximately 2.74 years.

Common Stock Warrants Outstandi

Common Stock Warrants Outstanding	3 Months Ended
	Mar. 31, 2021
Equity Classified Warrants [Abstract]
Common Stock Warrants Outstanding	8. Common Stock Warrants Outstanding A summary of equity-classified common stock warrant activity for the three months ended March 31, 2021 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2020 997,167 $ 35.48 3.3 Issued — — Exercised (5,304 ) 3.50 Expired — — Outstanding at March 31, 2021 991,863 $ 35.65 3.1 All warrants outstanding at December 31, 2020 and March 31, 2021 are exercisable. Warrants issued in the February 2019 financing transaction have an expiration date of February 12, 2024, warrants issued in the March 2019 transaction have an expiration date of September 19, 2024, warrants issued in the May 2019 inducement offering have an expiration date of December 2, 2024, warrants issued in December 2019 have an expiration date of December 11, 2024, and warrants issued in the January 2020 inducement offering have an expiration date of July 10, 2025. The intrinsic value of equity-classified common stock warrants outstanding at December 31, 2020 and March 31, 2021 was $243,000 and $404,000, respectively.

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) per Common Share	9. Net Income (Loss) per Common Share Basic and diluted net income (loss) per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three months ended March 31, 2020, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. For the three months ended March 31, 2021, there is net income attributable to common shareholders and, as a result, 256,461 warrants and 102,708 options were included in the calculation of dilutive weighted average shares in the money. As these shares were in the money at March 31, 2021, an additional 267,709 shares were included in the calculation of diluted net income per share. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the three months ended March 31, 2020, as they would be anti-dilutive, however, were considered in the calculation of diluted net income for the three months ended March 31, 2021: For the three months ended March 31, 2020 2021 Common warrants outstanding 1,527,076 991,863 RSUs outstanding 36 36 Convertible preferred stock outstanding (number of common stock equivalents) 47,139 46,651 Common options outstanding 1,078,704 1,213,284 Total common share equivalents 2,652,955 2,251,834

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. During the three months ended March 31, 2020 and 2021, total expense recorded in the Company’s unaudited statements of operations and comprehensive loss for sales tax and maintenance obligations associated with equipment financing arrangements was approximately $32,000 and $25,000, respectively. At December 31, 2020 and March 31, 2021, approximately $77,000 and $79,000, respectively, of such sales tax and maintenance obligations incurred but not paid were recorded in accrued other liabilities in the Company’s balance sheet (see Note 5). Future payments totaling approximately $353,000 for sales tax and maintenance obligations associated with financed equipment were due under equipment financing arrangements at March 31, 2021, which will be expensed as incurred (see Note 6).

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received payments totaling approximately $26,000 and $36,000 during the years ended December 31, 2019 and 2020, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement. On December 11, 2019, the Company entered into a First Amendment to Assignment and Exclusive Cross-License Agreement with Aegea pursuant to which the Company obtained a royalty bearing license for a certain patent. The Company agreed to pay Aegea, effective January 1, 2019, a royalty of 10% on Biocept’s sale of research use only, or RUO, and import research use only reagents and kits in the field of oncology, where the sample types are tissue, whole blood, bone marrow, cerebrospinal fluid or derivatives of any of the foregoing. As of December 31, 2020 and March 31, 2021, the Company has accrued approximately $2,900 and $1,700 for royalty expenses, respectively, related to this arrangement. On June 3, 2020, the Company entered into a development agreement with Aegea focused on the co-development by Biocept and Aegea of a highly sensitive PCR-based assay designed by Aegea for detecting the COVID-19 virus. Pursuant to the agreement, the Company receives compensation for development services performed based on time and materials expended. During the three months ended March 31, 2021, the Company recorded revenues of approximately $44,000, and as of December 31, 2020 and March 31, 2021 had approximately $132,000 and $72,000 accounts receivable due from Aegea related to this agreement. In February 2021, the Company entered into a supply agreement with Aegea for a new PCR-based COVID-19 assay kit designed by Aegea and co-developed by Aegea and the Company. Under the agreement, Aegea will supply the COVID-19 assay kit to the Company for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT). In the three months ended March 31, 2021, there has been no amounts exchanged under this agreement.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Subsequent to the three months ended March 31, 2021, the Company financed certain business insurance premiums totaling approximately $622,000 through third-parties.

The Company, Business Activit_2

The Company, Business Activities and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
The Company and Business Activities	The Company and Business Activities The Company was founded in California in May 1997 and is an early-stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC TM , provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly owned subsidiary of the Company since July 23, 2013. The COVID-19 pandemic continues to evolve, and the extent to which COVID-19 may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. While the Company experienced increased revenue levels in 2020 and the first quarter in 2021 related to its COVID-19 testing business and attained net income for the first time in its operating history in the fourth quarter in 2020, and again in the first quarter of 2021, these results are not expected to be indicative of future results as the COVID-19 pandemic subsides.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2020 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 31, 2021 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten. As such, all references to share and per share amounts in these financial statements and accompanying notes have been retroactively restated to reflect the one-for-ten reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-ten reverse stock split. A novel strain of coronavirus, or COVID COVID COVID
Significant Accounting Policies	Significant Accounting Policies During the three months ended March 31, 2021, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Revenue Recognition and Accounts Receivable	Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. Contracts For its commercial revenues, while the Company markets directly to physicians and other healthcare providers, the Company provides services that benefit the patient. Patients do not typically enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: • Approval of a contract is established via the order and accession, which are submitted by the patient’s physician. • The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. • Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided. • On ce the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status. • Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur. The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, such as pharma or biotech organizations, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks, and for our RT-PCR COVID-19 testing, typically 48 hours or less. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations. Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three months ended March 31, 2020 and 2021. Further, although the Company believes that its estimate for contractual allowances and other reserves is appropriate, it is possible that the Company will experience an impact on cash collections as a result of the impact of the COVID-19 pandemic. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service. Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable. Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses. The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses. Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three months ended March 31, 2020 and 2021 disaggregated by source and nature are as follows: For the three months ended March 31, 2020 2021 Net revenues from contracted payers* $ 500,188 $ 6,313,884 Net revenues from non-contracted payers 817,413 11,341,163 Development services revenues 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190 *Includes Medicare, Medicare Advantage, and CARES Act as reimbursement amounts are fixed. Revenues for the three months ended March 31, 2021 included $17.7 million in commercial test revenue, which includes $16.8 million attributable to RT-PCR COVID-19 testing. For the three months ended March 31, 2020 2021 Net commercial revenues recognized upon delivery $ 1,317,601 $ 17,655,047 Development services revenues recognized upon delivery 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190 At December 31, 2020 and March 31, 2021, unbilled account receivables total approximately $4.5 million and $4.3 million, respectively. Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2020 and 2021 were as follows: For the three months ended March 31, 2020 2021 Medicare and Medicare Advantage/CARES Act 37 % 35 % Blue Cross Blue Shield 29 % 30 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2020 and March 31, 2021 were as follows: December 31, 2020 March 31, 2021 Medicare and Medicare Advantage/CARES Act 35 % 37 % Blue Cross Blue Shield 24 % 28 %
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, “Credit Losses (Topic 326).” ASU 2016-13 requires that financial assets measured at amortized cost, such as trade receivables and investments, be represented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial asset. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In May 2019, the FASB issued ASU No. 2019-05, “Financial Instruments—Credit Losses (Topic 326) Targeted Transition Relief,” which allows for a transition election on certain instruments. The guidance is effective for Small Reporting Companies for fiscal years beginning after December 15, 2022 and interim periods in those fiscal years. In November 2019, the FASB issued ASU No. 2019-11 which amends certain aspects of ASU No. 2016-13, including transition relief for trouble debt restructuring, among other topics. The Company is currently evaluating the impact of this pronouncement on its financial statements.

The Company, Business Activit_3

The Company, Business Activities and Basis of Presentation (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Composition of Net Revenues Recognized Disaggregated by Source and Nature	The composition of the Company’s net revenues recognized during the three months ended March 31, 2020 and 2021 disaggregated by source and nature are as follows: For the three months ended March 31, 2020 2021 Net revenues from contracted payers* $ 500,188 $ 6,313,884 Net revenues from non-contracted payers 817,413 11,341,163 Development services revenues 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190 *Includes Medicare, Medicare Advantage, and CARES Act as reimbursement amounts are fixed. Revenues for the three months ended March 31, 2021 included $17.7 million in commercial test revenue, which includes $16.8 million attributable to RT-PCR COVID-19 testing. For the three months ended March 31, 2020 2021 Net commercial revenues recognized upon delivery $ 1,317,601 $ 17,655,047 Development services revenues recognized upon delivery 60,329 39,286 Kits and Blood Collection Tubes (BCT) 68,619 61,857 Total net revenues $ 1,446,549 $ 17,756,190
Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage	The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three months ended March 31, 2020 and 2021 were as follows: For the three months ended March 31, 2020 2021 Medicare and Medicare Advantage/CARES Act 37 % 35 % Blue Cross Blue Shield 29 % 30 % The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2020 and March 31, 2021 were as follows: December 31, 2020 March 31, 2021 Medicare and Medicare Advantage/CARES Act 35 % 37 % Blue Cross Blue Shield 24 % 28 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Assumptions Used for Determining Fair Values of Common Stock Warrants	The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: Beginning stock price $ 3.00 Exercise price $ 3.495 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.66 % Expected life (in years) 5.50 Expected volatility 150.33 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2021
Balance Sheet Components [Abstract]
Schedule of Balance Sheet Details	The following provides certain balance sheet details: December 31, March 31, 2020 2021 Inventories Raw materials $ 1,235,620 $ 2,406,901 Subassemblies 691,126 839,674 Finished goods 2,878 12,019 $ 1,929,624 $ 3,258,594 Fixed Assets Machinery and equipment $ 2,974,320 $ 2,962,742 Furniture and office equipment 156,987 156,987 Computer equipment and software 2,428,211 2,556,276 Leasehold improvements 570,173 95,990 Construction in process 761,221 485,359 Total fixed assets, gross 6,890,912 6,257,354 Less accumulated depreciation and amortization (4,573,296 ) (4,161,650 ) Total fixed assets, net $ 2,317,616 $ 2,095,704 Accrued Liabilities Accrued payroll $ 452,118 $ 772,342 Accrued vacation 868,557 952,885 Accrued bonuses 1,022,421 1,265,262 Accrued sales commissions 456,526 339,000 Accrued other 366,047 108,086 Total accrued liabilities $ 3,165,669 $ 3,437,575

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Right-Of-Use Lease Assets	The following schedule sets forth the components of right-of-use lease assets as of December 31, 2020 and March 31, 2021 as follows: December 31, March 31, 2020 2021 Lease right-of-use assets: Operating $ 9,776,349 $ 9,407,468 Finance 2,337,709 3,059,458 Total $ 12,114,058 $ 12,466,926
Schedule of Current Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2020 and March 31, 2021: December 31, March 31, 2020 2021 Current portion of lease liabilities: Operating $ — $ — Finance 963,726 1,179,557 Total $ 963,726 $ 1,179,557
Schedule of Long-Term Portion of Operating and Finance Lease Liabilities	The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2020 and March 31, 2021: December 31, March 31, 2020 2021 Long-term portion of lease liability: Operating $ 9,805,361 $ 9,798,146 Finance 1,459,550 1,816,463 Total $ 11,264,911 $ 11,614,609
Schedule of Lease Expenses	The following schedule represents the components of lease expense for the three months ended March 31, 2020 and March 31, 2021: For the three months ended March 31, 2020 March 31, 2021 Lease cost Finance lease cost Amortization of right-of-use assets $ 144,530 $ 172,325 Interest on lease liabilities 56,701 65,241 Operating lease cost 318,005 414,802 Total $ 519,236 $ 652,368
Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases	The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments as of March 31, 2021: Finance Operating Minimum Maintenance and Minimum Lease Sales Tax Obligation Lease Payments Payments Payments 2021 $ 981,740 $ 93,621 $ 495,590 2022 1,020,965 101,578 1,586,210 2023 873,830 85,427 1,629,025 2024 464,328 55,806 1,671,841 Thereafter 209,372 16,184 11,995,433 Total payments 3,550,235 352,616 17,378,099 Less amount representing interest (554,215 ) — (7,579,953 ) Present value of payments $ 2,996,020 $ 352,616 $ 9,798,146
Supplemental Cash Flow Information Related to Operating and Finance Leases	The following schedule sets forth supplemental cash flow information related to operating and finance leases as of March 31, 2020 and March 31, 2021: For the three months ended March 31, 2020 March 31, 2021 Other information Operating cash flows from finance leases $ 56,701 $ 65,241 Operating cash flows from operating leases $ 366,487 $ 53,136 Financing cash flows from finance leases $ 136,574 $ 321,330

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2021 is as follows: Weighted Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2020 1,078,704 $ 11.64 9.36 Granted 175,041 $ 5.70 Exercised — — Cancelled/forfeited/expired (40,461 ) $ 19.09 Outstanding at March 31, 2021 1,213,284 $ 10.44 9.31 Vested and unvested expected to vest at March 31, 2021 1,179,760 $ 10.60 9.31
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2021 were as follows: Stock and exercise prices $5.09 - $6.03 Expected dividend yield 0.00% Discount rate-bond equivalent yield 0.52% – 1.15% Expected life (in years) 5.39 – 5.98 Expected volatility 164.0% - 170.1%
Summary of RSU Activity	A summary of RSU activity for the three months ended March 31, 2021 is as follows: Weighted Number of Average Grant Shares Date Fair Value Outstanding at December 31, 2020 36 $ 4,158 Granted — — Vested and issued — — Forfeited — — Outstanding at March 31, 2021 36 $ 4,158 Vested at March 31, 2021 36 $ 4,158
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented: For the three months ended March 31, 2020 2021 Stock Options Cost of revenues $ 22,813 $ 94,264 Research and development expenses 24,435 44,316 General and administrative expenses 94,414 259,363 Sales and marketing expenses 1,302 62,258 Total expenses related to stock options 142,964 460,201

Common Stock Warrants Outstan_2

Common Stock Warrants Outstanding (Tables)	3 Months Ended
	Mar. 31, 2021
Equity Classified Warrants [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the three months ended March 31, 2021 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2020 997,167 $ 35.48 3.3 Issued — — Exercised (5,304 ) 3.50 Expired — — Outstanding at March 31, 2021 991,863 $ 35.65 3.1

Net Income (Loss) per Common _2

Net Income (Loss) per Common Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the three months ended March 31, 2020, as they would be anti-dilutive, however, were considered in the calculation of diluted net income for the three months ended March 31, 2021: For the three months ended March 31, 2020 2021 Common warrants outstanding 1,527,076 991,863 RSUs outstanding 36 36 Convertible preferred stock outstanding (number of common stock equivalents) 47,139 46,651 Common options outstanding 1,078,704 1,213,284 Total common share equivalents 2,652,955 2,251,834

The Company, Business Activit_4

The Company, Business Activities and Basis of Presentation - Additional Information (Detail)	Sep. 03, 2020shares	Mar. 31, 2021USD ($)shares	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)shares
The Company Business Activities And Basis Of Presentation [Line Items]
Stockholders equity reverse stock split ratio	0.1
Common stock, shares authorized | shares	150,000,000	150,000,000		150,000,000
Description of reverse stock split		On September 3, 2020, pursuant to the approval of the Company’s board of directors, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock using a ratio of one-for-ten.
Net revenues		$ 17,756,190	$ 1,446,549
Unbilled accounts receivables		4,300,000		$ 4,500,000
Commercial Test Revenue [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Net revenues		17,700,000
Commercial Test Revenue [Member] | RT-PCR COVID-19 Testing [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Net revenues		$ 16,800,000
ASC 606 [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Performance obligation, description of timing		The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks
Practical expedient, description		The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
ASC 606 [Member] | Maximum [Member] | Sales and Marketing Expenses [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Amortization period		1 year

The Company, Business Activit_5

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) - USD ($)		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 17,756,190	$ 1,446,549
Commercial Revenues [Member] | Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues	[1]	6,313,884	500,188
Commercial Revenues [Member] | Non-Contracted Payers [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		11,341,163	817,413
Development Services Revenues [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		39,286	60,329
Kits and Blood Collection Tubes [Member]
Disaggregation Of Revenue [Line Items]
Total net revenues		$ 61,857	$ 68,619
[1]	Includes Medicare, Medicare Advantage, and CARES Act as reimbursement amounts are fixed.

The Company, Business Activit_6

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 17,756,190	$ 1,446,549
Commercial Revenues [Member] | Net Commercial Revenues Recognized Upon Delivery [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	17,655,047	1,317,601
Development Services Revenues [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	39,286	60,329
Kits and Blood Collection Tubes [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 61,857	$ 68,619

The Company, Business Activit_7

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Customer Concentration Risk [Member] | Net Revenues [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	30.00%	29.00%
Customer Concentration Risk [Member] | Net Revenues [Member] | Cares Act [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	35.00%	37.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28.00%		24.00%
Credit Concentration Risk [Member] | Net Accounts Receivable [Member] | Cares Act [Member] | Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	37.00%		35.00%

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Cash And Cash Equivalents [Abstract]
Cash	$ 14,197,547		$ 14,367,942
Accumulated deficit	(260,927,575)		(263,526,867)
Net income (loss)	2,599,292	$ (8,341,338)	(17,800,000)
Cash flows from operations	843,825	$ (5,278,860)	$ (19,800,000)
Aggregate net interest-bearing indebtedness	3,000,000
Aggregate net interest-bearing indebtedness due within one year	1,200,000
Other non-interest-bearing current liabilities	$ 3,400,000

Sales of Equity Securities - Ad

Sales of Equity Securities - Additional Information (Detail) - USD ($)	Mar. 04, 2020	Mar. 02, 2020	Jan. 31, 2020	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2021	Mar. 31, 2020	Jan. 31, 2018
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants							$ 659,958
Proceeds from exercise of common stock warrants						$ 18,552	2,306,708
Stock price	$ 4.10	$ 4
Fair value of warrants issued			$ 1,900,000
Warrant inducement expense				$ 130,000	$ 60,000		$ 2,102,109
Shares issued in offering	1,600,000	2,300,000
Net cash proceeds from sale of securities	$ 6,100,000	$ 8,600,000
Warrant [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock								89,657
Stock price			$ 3.495					$ 4.05
Over-allotment Option [Member] | Warrant [Member]
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants			$ 700,000
Shares issued in offering			192,750
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member]
Class Of Stock [Line Items]
Proceeds from exercise of common stock warrants			$ 2,300,000
Warrant inducement expense			$ 191,000
February 2019 March 2019 Warrant Repricing and Exchange Transaction [Member] | Warrant [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock			692,725					692,725

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Jan. 10, 2020	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2021	Mar. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations				$ 894,000	$ 208,000
Estimated grant date fair value of warrants	$ 2.80
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,900,000
Exercise price of unregistered warrants	$ 3.495
Adjusted exercise price of warrants		$ 12.50	$ 12
Estimated fair value of warrants		2.70	2.70
Estimated fair value of warrants increased		$ 3	$ 2.90
Warrants eligible for price modification		476,000	216,725
Warrant inducement expense		$ 130,000	$ 60,000		$ 2,102,109
Warrant Inducement Transaction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants	$ 3.495
Class of warrant or rights, term	5 years 6 months
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock	692,725
Estimated Fair Value Measurements, Nonrecurring [Member] | Level 3 Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations				$ 894,000

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	Mar. 31, 2021$ / shares	Mar. 04, 2020$ / shares	Mar. 02, 2020$ / shares
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price		$ 4.10	$ 4
January 10, 2020 Warrant Inducement Transaction [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 3
January 10, 2020 Warrant Inducement Transaction [Member] | Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	3.495
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	0
January 10, 2020 Warrant Inducement Transaction [Member] | Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	1.66
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
January 10, 2020 Warrant Inducement Transaction [Member] | Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Measurement input	150.33

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Balance Sheet Details (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 2,406,901	$ 1,235,620
Subassemblies	839,674	691,126
Finished goods	12,019	2,878
Inventory Gross	3,258,594	1,929,624
Fixed Assets
Machinery and equipment	2,962,742	2,974,320
Furniture and office equipment	156,987	156,987
Computer equipment and software	2,556,276	2,428,211
Leasehold improvements	95,990	570,173
Construction in process	485,359	761,221
Total fixed assets, gross	6,257,354	6,890,912
Less accumulated depreciation and amortization	(4,161,650)	(4,573,296)
Total fixed assets, net	2,095,704	2,317,616
Accrued Liabilities
Accrued payroll	772,342	452,118
Accrued vacation	952,885	868,557
Accrued bonuses	1,265,262	1,022,421
Accrued sales commissions	339,000	456,526
Accrued other	108,086	366,047
Total accrued liabilities	$ 3,437,575	$ 3,165,669

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021USD ($)
Balance Sheet Components [Abstract]
Disposal of fixed assets	$ 4,000
Fixed assets acquired	$ 712,000

Leases - Additional Information

Leases - Additional Information (Detail)	Jun. 05, 2020USD ($)	Jun. 01, 2020USD ($)ft²	Mar. 31, 2020USD ($)mo	Feb. 29, 2020USD ($)mo	Mar. 31, 2021USD ($)mo	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Jan. 01, 2019USD ($)
Leases [Line Items]
Finance lease right-of-use assets					$ 3,059,458		$ 2,337,709
Total proceeds from equipment financing commitment			$ 11,000	$ 197,000	$ 894,000
Finance lease transaction, frequency of payments			monthly	monthly	monthly
Finance lease transaction, number of installments payments | mo			48
Finance lease transaction, monthly installments of principal and interest payments			$ 288	$ 4,532	$ 21,330
Finance lease transaction, total amount to be repaid			$ 14,000	$ 265,000	$ 1,064,000	$ 14,000
Finance lease transaction, commitment period			2024-02	2025-01	2026-03
Operating lease monthly payments					$ 53,136	366,487
Operating lease, right-of-use asset					9,407,468		9,776,349
Operating lease liability					$ 9,798,146
Finance lease, weighted average remaining lease term					3 years 3 months 7 days
Operating lease, weighted average remaining lease term					10 years 2 months 1 day
Finance lease, weighted average discount rate, percent					16.84%
Operating lease, weighted average discount rate, percent					12.00%
Right of use assets in exchange for finance lease liabilities					$ 894,000
ASC Topic 842 [Member]
Leases [Line Items]
Finance lease right-of-use assets								$ 1,400,000
Financed equipment					5,533,000		4,639,000
Accumulated depreciation related to financed equipment					2,474,000		2,302,000
Depreciation expense related to financed equipment					$ 172,000	$ 146,000
Operating lease transaction, frequency of payments					monthly cash payment
Operating lease monthly payments					$ 120,000
Operating lease term					Jul. 31, 2020
Operating lease, right-of-use asset								1,930,000
Operating lease liability								$ 2,201,000
Operating lease incremental borrowing rate								4.50%
ASC Topic 842 [Member] | 5810 Nancy Ridge Road in San Diego, California [Member]
Leases [Line Items]
Operating lease, right-of-use asset	$ 482,000
Operating lease liability	$ 482,000
Lessee, operating lease, option to extend					Pursuant to the Amendment, the expiration date of the Lease was extended from July 31, 2020 to November 30, 2020
Lease expire date	Nov. 30, 2020
Lessee, operating lease, existence of option to extend	true
Additional extension facility extending the lease	December 11, 2020
ASC Topic 842 [Member] | 9955 Mesa Rim Road in San Diego, California [Member]
Leases [Line Items]
Operating lease monthly payments		$ 128,000
Operating lease, right-of-use asset							9,776,000
Operating lease liability							$ 9,805,000
Operating lease incremental borrowing rate							12.00%
Lease agreement | ft²		39,000
Lease commenced date		Dec. 1, 2020
Lessee, operating lease, term of contract		127 months
Lease term, description					The lease includes a rent abatement period of seven months, from January 2021 through July of 2021, during which period the Company is exempted from paying the amount of base rent of $111,000.
Rent Expense		$ 111,000
Leasehold improvement allowance		1,586,000
Additional leasehold improvement allowance		$ 1,586,000
Additional rent payment of percentage		7.00%
Additional rent payment		$ 18,000
Lessee operating lease initial monthly lease payments		$ 140,000
Reimbursable leasehold improvement costs					$ 361,000		$ 1,631,000
Minimum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo				48	36
Minimum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life			3 years			3 years
Maximum [Member]
Leases [Line Items]
Finance lease transaction, number of installments payments | mo				60	60
Maximum [Member] | ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life			7 years			7 years

Leases - Schedule of Right-Of-U

Leases - Schedule of Right-Of-Use Lease Assets (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Lease right-of-use assets:
Operating	$ 9,407,468	$ 9,776,349
Finance	3,059,458	2,337,709
Total	$ 12,466,926	$ 12,114,058

Leases - Schedule of Current Po

Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current portion of lease liabilities:
Finance	$ 1,179,557	$ 963,726
Total	$ 1,179,557	$ 963,726

Leases - Schedule of Long-Term

Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Long-term portion of lease liability:
Operating	$ 9,798,146	$ 9,805,361
Finance	1,816,463	1,459,550
Total	$ 11,614,609	$ 11,264,911

Leases - Schedule of Lease Expe

Leases - Schedule of Lease Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Finance lease cost
Amortization of right-of-use assets	$ 172,325	$ 144,530
Interest on lease liabilities	65,241	56,701
Operating lease cost	414,802	318,005
Total	$ 652,368	$ 519,236

Leases - Schedule of Remaining

Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail)	Mar. 31, 2021USD ($)
Financing Lease Minimum Payment Abstract
2021	$ 981,740
2022	1,020,965
2023	873,830
2024	464,328
Thereafter	209,372
Total payments	3,550,235
Less amount representing interest	(554,215)
Present value of payments	2,996,020
Financing Lease Maintenance and Sales Tax Obligation Payments Abstract
2021	93,621
2022	101,578
2023	85,427
2024	55,806
Thereafter	16,184
Total payments	352,616
Present value of payments	352,616
Operating Lease Minimum Payment Abstract
2021	495,590
2022	1,586,210
2023	1,629,025
2024	1,671,841
Thereafter	11,995,433
Total payments	17,378,099
Less amount representing interest	(7,579,953)
Present value of payments	$ 9,798,146

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other information
Operating cash flows from finance leases	$ 65,241	$ 56,701
Operating cash flows from operating leases	53,136	366,487
Financing cash flows from finance leases	$ 321,330	$ 136,574

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Jun. 05, 2020shares	Dec. 31, 2020USD ($)shares	Mar. 31, 2021USD ($)Planshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans | Plan			2
Total Shares Outstanding		1,078,704	1,213,284
Unrecognized share-based compensation expense, weighted-average recognition period			2 years 8 months 26 days
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding | $		$ 61,515	$ 4,714
Intrinsic value of options exercisable | $		61,515	4,714
Intrinsic value of options vested and unvested expected to vest | $		$ 61,515	4,714
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value shares, RSUs outstanding | $			200
Intrinsic value amount, RSUs vested | $			$ 200
RSUs outstanding		36	36
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense, stock options | $			$ 4,709,384
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			762,421
2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance	730,000
Total stock options and RSUs authorized			1,036,409
Stock options and RSUs issued			988,101
Total Shares Outstanding			993,172
Common stock, shares authorized			32,220
2013 Equity Incentive Plan [Member] | Inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares of common stock authorized for issuance		750,000
Total stock options and RSUs authorized			761,836
Stock options and RSUs issued			259,542
Total Shares Outstanding			268,882
Common stock, shares authorized			502,210

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	1,078,704
Number of Shares, Granted	175,041
Number of Shares, Cancelled/forfeited/expired	(40,461)
Number of Shares Outstanding, Ending Balance	1,213,284	1,078,704
Number of Shares, Vested and unvested expected to vest, Ending Balance	1,179,760
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 11.64
Weighted Average Exercise Price Per Share, Granted	5.70
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	19.09
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	10.44	$ 11.64
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 10.60
Weighted Average Remaining Contractual Term in Years, Outstanding	9 years 3 months 21 days	9 years 4 months 9 days
Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest	9 years 3 months 21 days

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2021$ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected volatility, Minimum	164.00%
Expected volatility, Maximum	170.10%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 5.09
Discount rate-bond equivalent yield	0.52%
Expected life (in years)	5 years 4 months 20 days
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 6.03
Discount rate-bond equivalent yield	1.15%
Expected life (in years)	5 years 11 months 23 days

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member]	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance | shares	36
Number of Shares, Granted | shares	0
Number of share, Vested and issued | shares	0
Number of share, Forfeited | shares	0
Number of Shares Outstanding, Ending Balance | shares	36
Number of Shares, Vested, Ending Balance | shares	36
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance | $ / shares	$ 4,158
Weighted Average Grant Date Fair Value, Granted | $ / shares	0
Weighted Average Grant Date Fair Value, Vested and issued | $ / shares	0
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	0
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance | $ / shares	4,158
Weighted Average Grant Date Fair Value, Vested, Ending Balance | $ / shares	$ 4,158

Stock-Based Compensation - Effe

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - Stock Options [Member] - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 460,201	$ 142,964
Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	94,264	22,813
Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	44,316	24,435
General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	259,363	94,414
Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 62,258	$ 1,302

Common Stock Warrants Outstan_3

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	997,167
Number of Shares, Exercised	(5,304)
Number of Shares, Outstanding, Ending Balance	991,863	997,167
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 35.48
Weighted Average Exercise Price Per Share, Exercised	3.50
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 35.65	$ 35.48
Average Remaining Contractual Term (in years)	3 years 1 month 6 days	3 years 3 months 18 days

Common Stock Warrants Outstan_4

Common Stock Warrants Outstanding - Additional Information (Detail) - USD ($)	1 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	May 31, 2019	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2021	Dec. 31, 2020
Class Of Warrant Or Right [Line Items]
Common stock warrants outstanding, intrinsic value						$ 404,000	$ 243,000
Warrants [Member] | February 2019 Financing Transaction [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date					Feb. 12, 2024
Warrants [Member] | March 2019 Transaction [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date				Sep. 19, 2024
Warrants [Member] | May 2019 Inducement Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date			Dec. 2, 2024
Warrants [Member] | December 2019 Underwritten Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date		Dec. 11, 2024
Warrants [Member] | January 2020 Inducement Offering [Member]
Class Of Warrant Or Right [Line Items]
Class of warrant or rights, expiration date	Jul. 10, 2025

Net Income (Loss) per Common _3

Net Income (Loss) per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021shares
Earnings Per Share [Abstract]
Number of warrants included in the calculation of dilutive weighted average shares	256,461
Number of options included in the calculation of dilutive weighted average shares	102,708
Additional shares included in the calculation of diluted net income per share	267,709

Net Income (Loss) per Common _4

Net Income (Loss) per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents	2,251,834	2,652,955
Common Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents	991,863	1,527,076
RSUs [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents	36	36
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents	1,213,284	1,078,704
Convertible Preferred Stock Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common share equivalents	46,651	47,139

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Loss Contingencies [Line Items]
Total expense for sales tax and maintenance obligations	$ 25,000	$ 32,000
Total payments for future sales tax and maintenance obligations	352,616
Accrued Other Liabilities [Member]
Loss Contingencies [Line Items]
Sales tax and maintenance obligations incurred but not paid	$ 79,000		$ 77,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	Jan. 01, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Revenues		$ 17,756,190	$ 1,446,549
Development Services Revenues [Member]
Related Party Transaction [Line Items]
Revenues		39,286	$ 60,329
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs				$ 36,000	$ 26,000
Percentage of royalty on sale of product	10.00%
Accrued royalty expense		1,700		2,900
Accounts receivable		72,000		$ 132,000
Aegea Biotechnologies, Inc [Member] | Supply Agreement [Member]
Related Party Transaction [Line Items]
Amounts exchanged for agreement		0
Aegea Biotechnologies, Inc [Member] | Development Services Revenues [Member]
Related Party Transaction [Line Items]
Revenues		$ 44,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	May 13, 2021USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Financed insurance premium through third party financing	$ 622,000